No Data
Baipu Sais (301080.SZ): has repurchased a total of 0.11% of shares.
On April 2, Gelonghui reported that Baiposais (301080.SZ) announced that as of March 31, 2025, the company has repurchased a total of 133,100 shares through a dedicated securities account for share buybacks via centralized bidding, accounting for 0.1109% of the company's total shares, with the highest Fill Price at 48.45 yuan/share, the lowest Fill Price at 41.82 yuan/share, and the total transaction amount being 5.99595 million yuan (excluding transaction fees).
Acrobiosystems Co.,Ltd.'s (SZSE:301080) Most Bullish Insider Is CEO Yiding Chen, and Their Holdings Value Went up by 5.6% Last Week
Investors Appear Satisfied With Acrobiosystems Co.,Ltd.'s (SZSE:301080) Prospects As Shares Rocket 26%
Here's Why AcrobiosystemsLtd (SZSE:301080) Can Manage Its Debt Responsibly
Baipusais (301080.SZ): Expected net income in 2024 to decrease by 8.85%-21.87% year-on-year.
On January 16, Gelonghui announced that Baipusais (301080.SZ) expects its revenue for 2024 to be between 645 million yuan and -660 million yuan, an increase of 18.64% to 21.40% compared to the same period last year. Net income is expected to be between 120 million yuan and -140 million yuan, a decrease of 8.85% to 21.87% compared to the same period last year. The non-net profit is expected to be between 110 million yuan and -130 million yuan, a decrease of 7.41% to 21.65% compared to the same period last year. The company provides precise services for the biopharmaceutical and cellular immunotherapy industries.
Bepsyth: 2024 Annual Results Forecast